Hjem › Akut myelogen leukemi › Kansas › Overland Park
Kliniske studier for Akut myelogen leukemi i Overland Park, KS
11 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Overland Park (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
RekruttererFase 3
- US-Kansas City KS-KUMC, Fairway · 3 mi unna
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
RekruttererFase 1
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi unna
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- The University of Kansas Medical Center Research Institute, Fairway · 3 mi unna
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
RekruttererFase 1
- University of Kansas, Fairway · 3 mi unna
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RekruttererFase 2
- University of Kansas Cancer Center, Fairway · 3 mi unna
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
RekruttererFase 1
- University of Kansas Cancer Center, Fairway · 3 mi unna
Akut myelogen leukemi-studier i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Seattle, WA41 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA31 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
Andre studier i Overland Park
- Ikke-småcellet lungekreft16 studier
- Lungekreft11 studier
- Brystkreft10 studier
- Atrieflimmer8 studier
- Kolorektal kreft8 studier
- Fedme7 studier
- Pankreaskreft7 studier
- Prostatakreft7 studier
- Melanom6 studier
- Overvekt6 studier
- Eggstokkreft6 studier
- Kreft (alle typer)5 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.